Takeda Hosts Wave 1 Pipeline Market Call
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced a conference call on April 6, 2021, to discuss updates on its Wave 1 pipeline portfolio, which includes several New Molecular Entities (NMEs) with regulatory filings expected by year-end FY2021. The agenda features key presentations on innovative treatments, including Maribavir (TAK-620) for post-transplant CMV infection and Soticlestat (TAK-935) for Dravet Syndrome. Takeda emphasizes its focus on organic and sustainable revenue growth over the coming years.
- Upcoming regulatory filings for multiple New Molecular Entities (NMEs) by year-end FY2021.
- Focus on innovative treatments targeting significant medical needs, such as Maribavir and Soticlestat.
- None.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME regulatory filings expected by year-end FY2021, the company will outline plans for organic and sustainable revenue growth over the next several years.
Date
April 6, 2021
Time
8:00 a.m. – 10:30 a.m. ET / 9:00 p.m. – 11:30 p.m. JT
Agenda
The agenda for Takeda’s call is as follows:
TIME (ET) |
TIME (JT) |
Session/Speaker |
8:00 a.m. – 8:05 a.m. |
9:00 p.m. – 9:05 p.m. |
Introduction
|
8:05 a.m. – 8:10 a.m. |
9:05 p.m. – 9:10 p.m. |
Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs Andy Plump, president of Research and Development |
8:10 a.m. – 8:35 a.m. |
9:10 p.m. – 9:35 p.m. |
Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection
Claus Jepsen, head of Global Product and Launch Strategy, Rare Genetic and Hematology Therapeutic Area Unit |
8:35 a.m. – 8:40a.m. |
9:35 p.m. – 9:40p.m. |
Break |
8:40 a.m. – 9:00 a.m. |
9:40 p.m. – 10:00 p.m. |
Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome Sarah Sheikh, head of Neuroscience Therapeutic Area Unit Erika Gill, head of Global Product and Launch Strategy, Neuroscience Therapeutic Area |
9:00 a.m. – 9:35 a.m. |
10:00 p.m. – 10:35 p.m. |
Orexin Franchise Strategy Update: First Potential Medicine to Treat the Underlying Disease in Patients with Narcolepsy Type 1 Elena Koundourakis, head of Orexin Franchise Development, Neuroscience Therapeutic Area Erika Gill, head of Global Product and Launch Strategy, Neuroscience Therapeutic Area |
9:35 a.m. – 9:40 a.m. |
10:35 p.m. – 10:40 p.m. |
Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs Ramona Sequeira, president of U.S. Business Unit & Global Portfolio Commercialization |
9:40 a.m. – 10:30 a.m. |
{
"@context": "https://schema.org",
"@type": "FAQPage",
"name": "Takeda Hosts Wave 1 Pipeline Market Call FAQs",
"mainEntity": [
{
"@type": "Question",
"name": "What is the date of Takeda's conference call?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The conference call is scheduled for April 6, 2021."
}
},
{
"@type": "Question",
"name": "What time will Takeda's conference call occur?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The call will be from 8:00 a.m. to 10:30 a.m. ET."
}
},
{
"@type": "Question",
"name": "What key topics will be discussed during Takeda's conference call?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Key topics include updates on New Molecular Entities and innovative treatments in the Wave 1 pipeline."
}
},
{
"@type": "Question",
"name": "What is Maribavir (TAK-620) and its significance?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Maribavir (TAK-620) is being positioned as a potential game changer for post-transplant Cytomegalovirus infections."
}
},
{
"@type": "Question",
"name": "What therapeutic areas does Takeda's conference call cover?",
"acceptedAnswer": {
"@type": "Answer",
"text": "The call covers Rare Genetic, Hematology, and Neuroscience therapeutic areas."
}
}
]
}
|
